Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Elliot Sigal. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Elliot Sigal har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:ONCE / Spark Therapeutics, Inc. | Director | 0 |
US:MJN / Mead Johnson Nutrition Co. | Director | 0 |
US:BMY / Bristol-Myers Squibb Company | EVP, CSO & President R&D, Director | 25 000 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Elliot Sigal. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Elliot Sigal som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-12-17 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | −25 786 | 0 | −100,00 | ||||
2019-12-17 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | −17 203 | 0 | −100,00 | ||||
2019-12-17 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | −6 000 | 0 | −100,00 | ||||
2019-12-17 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | −4 000 | 0 | −100,00 | ||||
2019-12-17 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | −4 000 | 0 | −100,00 | ||||
2019-12-17 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
U - Other | −14 214 | 0 | −100,00 | 114,50 | −1 627 503 | ||
2019-06-03 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | −1 500 | 0 | −100,00 | ||||
2019-06-03 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
M - Exercise | 1 500 | 14 214 | 11,80 | ||||
2018-05-31 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | −1 500 | 0 | −100,00 | ||||
2018-05-31 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
M - Exercise | 1 500 | 12 714 | 13,38 | ||||
2018-05-31 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 4 000 | 4 000 | |||||
2018-05-31 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Restricted Stock Units |
A - Award | 1 500 | 1 500 | |||||
2018-04-16 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
S - Sale | −29 | 11 214 | −0,26 | 72,43 | −2 100 | 812 230 | |
2018-04-16 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
P - Purchase | 29 | 11 243 | 0,26 | 90,75 | 2 632 | 1 020 302 | |
2017-06-15 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Units |
D - Sale to Issuer | −1 709 | 0 | −100,00 | 90,00 | −153 810 | ||
2017-06-15 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
D - Sale to Issuer | −5 180 | 0 | −100,00 | 90,00 | −466 200 | ||
2017-06-15 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
D - Sale to Issuer | −5 180 | 0 | −100,00 | 90,00 | −466 200 | ||
2017-06-15 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
D - Sale to Issuer | −2 590 | 0 | −100,00 | 90,00 | −233 100 | ||
2017-06-15 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
D - Sale to Issuer | −13 721 | 0 | −100,00 | 90,00 | −1 234 890 | ||
2017-06-02 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Restricted Stock Units |
A - Award | 1 500 | 1 500 | |||||
2017-06-02 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 4 000 | 4 000 | |||||
2017-03-02 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
M - Exercise | −2 373 | 0 | −100,00 | ||||
2017-03-02 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
M - Exercise | 2 373 | 13 721 | 20,91 | ||||
2017-03-02 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
A - Award | 1 709 | 1 709 | |||||
2016-06-03 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 6 000 | 6 000 | |||||
2016-03-01 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
M - Exercise | 2 373 | 2 373 | |||||
2016-03-01 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
M - Exercise | −1 678 | 0 | −100,00 | ||||
2016-03-01 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
M - Exercise | 1 678 | 11 348 | 17,35 | ||||
2015-03-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
M - Exercise | −2 146 | 0 | −100,00 | ||||
2015-03-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
M - Exercise | 2 146 | 9 670 | 28,52 | ||||
2015-02-27 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
A - Award | 1 678 | 1 678 | |||||
2015-02-06 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | −31 559 | 0 | −100,00 | ||||
2015-02-06 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Series B Preferred Stock |
A - Award | 503 | 31 559 | 1,62 | ||||
2015-02-06 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
P - Purchase | 5 000 | 11 214 | 80,46 | 23,00 | 115 000 | 257 922 | |
2015-02-06 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
C - Conversion | 31 559 | 31 559 | |||||
2015-01-29 | 3 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
12 428 | ||||||||
2015-01-29 | 3 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
12 428 | ||||||||
2014-03-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
A - Award | 2 146 | 2 146 | |||||
2014-03-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
M - Exercise | −1 876 | 0 | −100,00 | ||||
2014-03-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
M - Exercise | 1 876 | 7 524 | 33,22 | ||||
2013-06-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −98 875 | 25 000 | −79,82 | ||||
2013-06-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −83 647 | 148 221 | −36,08 | 48,18 | −4 030 112 | 7 141 288 | |
2013-06-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 98 875 | 231 868 | 74,35 | 27,01 | 2 670 614 | 6 262 755 | |
2013-05-31 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −50 000 | 0 | −100,00 | ||||
2013-05-31 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −120 625 | 123 875 | −49,34 | ||||
2013-05-31 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −143 521 | 132 993 | −51,90 | 47,23 | −6 778 497 | 6 281 259 | |
2013-05-31 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 50 000 | 276 514 | 22,07 | 24,74 | 1 237 000 | 6 840 956 | |
2013-05-31 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 120 625 | 226 514 | 113,92 | 27,01 | 3 258 081 | 6 118 143 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −202 405 | 50 000 | −80,19 | ||||
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −103 500 | 0 | −100,00 | ||||
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −459 | 9 091 | −4,81 | 39,65 | −18 199 | 360 458 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −919 | 18 180 | −4,81 | 39,65 | −36 438 | 720 837 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −919 | 18 180 | −4,81 | 39,65 | −36 438 | 720 837 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −175 143 | 105 889 | −62,32 | 39,61 | −6 937 414 | 4 194 263 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −90 234 | 281 032 | −24,30 | 39,61 | −3 574 169 | 11 131 678 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −88 132 | 371 266 | −19,18 | 39,63 | −3 492 671 | 14 713 272 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 103 500 | 459 398 | 29,08 | 25,45 | 2 634 075 | 11 691 679 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 202 405 | 355 898 | 131,87 | 24,74 | 5 007 500 | 8 804 917 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −36 503 | 252 405 | −12,63 | ||||
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −11 092 | 288 908 | −3,70 | ||||
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −25 795 | 0 | −100,00 | ||||
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −9 157 | 9 550 | −48,95 | 39,97 | −366 005 | 381 714 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −18 313 | 19 099 | −48,95 | 39,97 | −731 971 | 763 387 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −18 313 | 19 099 | −48,95 | 39,97 | −731 971 | 763 387 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −41 868 | 153 493 | −21,43 | 39,92 | −1 671 371 | 6 127 441 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −31 594 | 195 361 | −13,92 | 39,90 | −1 260 601 | 7 794 904 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −21 856 | 226 955 | −8,78 | 39,90 | −872 054 | 9 055 504 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −9 600 | 248 811 | −3,72 | 40,00 | −384 000 | 9 952 440 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 11 092 | 258 411 | 4,48 | 24,74 | 274 416 | 6 393 088 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 25 795 | 247 319 | 11,64 | 22,73 | 586 320 | 5 621 561 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 36 503 | 221 524 | 19,73 | 24,74 | 903 084 | 5 480 504 | |
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
A - Award | 29 630 | 29 630 | |||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
J - Other | 845 | 22 011 | 3,99 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 21 166 | 21 166 | |||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
J - Other | 2 466 | 64 243 | 3,99 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 27 866 | 61 777 | 82,17 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
M - Exercise | −99 812 | 0 | −100,00 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
J - Other | 3 832 | 99 812 | 3,99 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 29 007 | 95 980 | 43,31 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −8 801 | 26 406 | −25,00 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −12 062 | 35 491 | −25,37 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −11 715 | 47 553 | −19,77 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −51 754 | 185 021 | −21,86 | 37,53 | −1 942 328 | 6 943 838 | |
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −9 343 | 236 775 | −3,80 | 37,53 | −350 643 | 8 886 166 | |
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −8 748 | 246 118 | −3,43 | 37,53 | −328 312 | 9 236 809 | |
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −5 194 | 254 866 | −2,00 | 37,53 | −194 931 | 9 565 121 | |
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 1 216 | 260 060 | 0,47 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 5 156 | 258 844 | 2,03 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 5 957 | 253 688 | 2,40 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 8 801 | 247 731 | 3,68 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 11 715 | 238 930 | 5,16 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 12 062 | 227 215 | 5,61 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 99 812 | 215 153 | 86,54 | ||||
2013-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Restricted Stock Units |
M - Exercise | −7 453 | 0 | −100,00 | ||||
2013-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −3 865 | 115 341 | −3,24 | 36,94 | −142 773 | 4 260 697 | |
2013-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 7 453 | 119 206 | 6,67 | ||||
2013-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Restricted Stock Units |
M - Exercise | −46 365 | 46 367 | −50,00 | ||||
2013-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −24 041 | 111 753 | −17,70 | 37,15 | −893 123 | 4 151 624 | |
2013-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 46 365 | 135 794 | 51,85 | ||||
2013-03-04 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
M - Exercise | −1 789 | 0 | −100,00 | ||||
2013-03-04 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
M - Exercise | 1 789 | 5 648 | 46,36 | ||||
2013-03-04 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
A - Award | 1 876 | 1 876 | |||||
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Option (right to buy) |
M - Exercise | −48 333 | 0 | −100,00 | ||||
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −70 000 | 25 795 | −73,07 | ||||
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −147 749 | 0 | −100,00 | ||||
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −224 705 | 89 429 | −71,53 | 36,79 | −8 266 897 | 3 290 093 | |
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 48 333 | 314 134 | 18,18 | 28,11 | 1 358 641 | 8 830 307 | |
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 70 000 | 265 801 | 35,75 | 22,73 | 1 591 100 | 6 041 657 | |
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 147 749 | 195 801 | 307,48 | 17,51 | 2 587 085 | 3 428 476 | |
2012-12-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −62 903 | 37 412 | −62,71 | 33,00 | −2 075 799 | 1 234 596 | |
2012-12-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −62 903 | 37 412 | −62,71 | 33,00 | −2 075 799 | 1 234 596 | |
2012-12-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −31 451 | 18 707 | −62,70 | 33,00 | −1 037 883 | 617 331 | |
2012-12-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
G - Gift | 100 315 | 100 315 | |||||
2012-12-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
G - Gift | 100 315 | 100 315 | |||||
2012-12-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
G - Gift | −200 630 | 50 158 | −80,00 | ||||
2012-12-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
G - Gift | 5 180 | 5 180 | |||||
2012-12-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
G - Gift | 5 180 | 5 180 | |||||
2012-12-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
G - Gift | −10 360 | 2 590 | −80,00 | ||||
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
J - Other | −4 | 0 | −100,00 | 71,35 | −282 | ||
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 4 | 4 | 71,35 | 282 | 282 | ||
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
J - Other | −1 083 | 0 | −100,00 | 74,19 | −80 361 | ||
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 4 | 1 083 | 0,37 | 68,11 | 275 | 73 779 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 4 | 1 079 | 0,38 | 69,04 | 282 | 74 508 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 5 | 1 075 | 0,45 | 58,33 | 279 | 62 711 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 4 | 1 070 | 0,36 | 62,30 | 238 | 66 681 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 4 | 1 067 | 0,40 | 56,25 | 240 | 59 991 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 5 | 1 062 | 0,45 | 50,53 | 241 | 53 675 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 5 | 1 057 | 0,43 | 52,90 | 241 | 55 940 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 4 | 1 053 | 0,42 | 46,81 | 208 | 49 287 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 9 | 1 048 | 0,84 | 44,58 | 389 | 46 741 | |
2012-09-07 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
J - Other | −12 950 | 16 809 | −43,52 | ||||
2012-09-07 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | −250 788 | 298 840 | −45,63 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Restricted Stock Units |
M - Exercise | −6 875 | 0 | −100,00 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
J - Other | 1 457 | 33 911 | 4,49 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 32 454 | 32 454 | |||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
M - Exercise | −78 955 | 66 973 | −54,11 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
J - Other | 2 879 | 145 928 | 2,01 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 28 152 | 143 049 | 24,50 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 33 783 | 114 897 | 41,65 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
A - Award | 35 207 | 35 207 | |||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −36 597 | 298 840 | −10,91 | 32,33 | −1 183 181 | 9 661 497 | |
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −3 187 | 335 437 | −0,94 | 32,33 | −103 036 | 10 844 678 | |
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 6 875 | 338 624 | 2,07 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 78 955 | 331 749 | 31,23 | ||||
2012-03-06 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Units |
M - Exercise | −1 699 | 1 789 | −48,71 | 78,26 | −132 964 | 140 007 | |
2012-03-06 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Units |
A - Award | 1 789 | 3 488 | 105,30 | ||||
2012-03-06 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
M - Exercise | 1 699 | 16 809 | 11,24 | 78,26 | 132 964 | 1 315 472 | |
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Restricted Stock Units |
M - Exercise | −7 453 | 7 453 | −50,00 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −3 455 | 252 794 | −1,35 | 32,59 | −112 598 | 8 238 556 | |
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 7 453 | 256 249 | 3,00 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Restricted Stock Units |
M - Exercise | −46 365 | 92 732 | −33,33 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −21 491 | 248 796 | −7,95 | 32,59 | −700 392 | 8 108 262 | |
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 46 365 | 270 287 | 20,71 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −12 062 | 59 268 | −16,91 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −7 383 | 223 922 | −3,19 | 32,59 | −240 612 | 7 297 618 | |
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 3 866 | 231 305 | 1,70 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 12 062 | 227 439 | 5,60 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −11 714 | 71 330 | −14,11 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −5 412 | 215 377 | −2,45 | 32,64 | −176 648 | 7 029 905 | |
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 3 173 | 220 789 | 1,46 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 11 714 | 217 616 | 5,69 | ||||
2011-12-29 |
|
4/A | BMY |
BRISTOL MYERS SQUIBB CO
Restricted Stock Units |
M - Exercise | −6 875 | 13 750 | −33,33 | ||||
2009-03-12 | 3 | MJN |
Mead Johnson Nutrition Co
Common Stock |
5 000 | ||||||||
2003-08-04 |
|
4 | (BMY) |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −1 219 | 75 024 | −1,60 |